Literature DB >> 29743187

Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.

Zhibo Gai1, Michele Visentin1, Ting Gui1, Lin Zhao1, Wolfgang E Thasler1, Stephanie Häusler1, Ivan Hartling1, Alessio Cremonesi1, Christian Hiller1, Gerd A Kullak-Ublick2.   

Abstract

Inflammation has a recognized role in nonalcoholic fatty liver disease (NAFLD) progression. In the present work, we studied the effect of high-fat diet (HFD) on arachidonic acid metabolism in the liver and investigated the role of the farnesoid X receptor (FXR, NR1H4) in eicosanoid biosynthetic pathways and nuclear factor κ light-chain enhancer of activated B cells (NF-kB) signaling, major modulators of the inflammatory cascade. Mice were fed an HFD to induce NAFLD and then treated with the FXR ligand obeticholic acid (OCA). Histology and gene expression analyses were performed on liver tissue. Eicosanoid levels were measured from serum and urine samples. The molecular mechanism underlying the effect of FXR activation on arachidonic acid metabolism and NF-kB signaling was studied in human liver Huh7 cells and primary cultured hepatocytes. NAFLD was characterized by higher (∼25%) proinflammatory [leukotrienes (LTB4)] and lower (∼3-fold) anti-inflammatory [epoxyeicosatrienoic acids (EETs)] eicosanoid levels than in chow mice. OCA induced the expression of several hepatic cytochrome P450 (P450) epoxygenases, the enzymes responsible for EET synthesis, and mitigated HFD-induced hepatic injury. In vitro, induction of CYP450 epoxygenases was sufficient to inhibit NF-kB signaling and cell migration. The CYP450 epoxygenase pan-inhibitor gemfibrozil fully abolished the protective effect of OCA, indicating that OCA-mediated inhibition of NF-kB signaling was EET-dependent. In summary, NAFLD was characterized by an imbalance in arachidonate metabolism. FXR activation reprogramed arachidonate metabolism by inducing P450 epoxygenase expression and EET production. In vitro, FXR-mediated NF-kB inhibition required active P450 epoxygenases.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29743187     DOI: 10.1124/mol.117.111047

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

1.  HBx-K130M/V131I Promotes Liver Cancer in Transgenic Mice via AKT/FOXO1 Signaling Pathway and Arachidonic Acid Metabolism.

Authors:  Amy P Chiu; Barbara R Tschida; Tung-Ting Sham; Lilian H Lo; Branden S Moriarity; Xiao-Xiao Li; Regina C Lo; David E Hinton; Dewi K Rowlands; Chi-On Chan; Daniel K W Mok; David A Largaespada; Nadia Warner; Vincent W Keng
Journal:  Mol Cancer Res       Date:  2019-04-11       Impact factor: 5.852

Review 2.  Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.

Authors:  Justin D Schumacher; Grace L Guo
Journal:  Handb Exp Pharmacol       Date:  2019

3.  Farnesoid X receptor regulates PI3K/AKT/mTOR signaling pathway, lipid metabolism, and immune response in hybrid grouper.

Authors:  Jia Xu; Xinzhou Yao; Xiaoyue Li; Shiwei Xie; Shuyan Chi; Shuang Zhang; Junming Cao; Beiping Tan
Journal:  Fish Physiol Biochem       Date:  2022-10-10       Impact factor: 3.014

Review 4.  Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.

Authors:  Ting-Ying Jiao; Yuan-di Ma; Xiao-Zhen Guo; Yun-Fei Ye; Cen Xie
Journal:  Acta Pharmacol Sin       Date:  2022-02-25       Impact factor: 7.169

Review 5.  The role of bile acids in cholestatic liver injury.

Authors:  Shi-Ying Cai; James L Boyer
Journal:  Ann Transl Med       Date:  2021-04

Review 6.  Bile acids and their receptors: modulators and therapeutic targets in liver inflammation.

Authors:  Anna Bertolini; Romina Fiorotto; Mario Strazzabosco
Journal:  Semin Immunopathol       Date:  2022-04-12       Impact factor: 11.759

7.  Farnesoid X receptor activation inhibits TGFBR1/TAK1-mediated vascular inflammation and calcification via miR-135a-5p.

Authors:  Chao Li; Shijun Zhang; Xiaoqing Chen; Jingkang Ji; Wenqing Yang; Ting Gui; Zhibo Gai; Yunlun Li
Journal:  Commun Biol       Date:  2020-06-24

Review 8.  Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease.

Authors:  Ludovico Abenavoli; Tetyana Falalyeyeva; Luigi Boccuto; Olena Tsyryuk; Nazarii Kobyliak
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-11

Review 9.  An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease.

Authors:  Ke Pei; Ting Gui; Dongfang Kan; Huichao Feng; Yanqiang Jin; Ying Yang; Qian Zhang; Ziwei Du; Zhibo Gai; Jibiao Wu; Yunlun Li
Journal:  Biomed Res Int       Date:  2020-07-18       Impact factor: 3.411

Review 10.  Update on FXR Biology: Promising Therapeutic Target?

Authors:  Chang Yeob Han
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.